Evidence map›Paper›PMID 42794585›Full record

ArticleInternational journal of molecular sciences2026

A Comparative Assessment of the Antifibrotic Effect of Nintedanib Administered via a Medicated Diet or Oral Gavage in a Rat Model of Bleomycin-Induced Pulmonary Fibrosis.

Vanessa Pitozzi, Paola Caruso, Silvia Pontis, Francesca Ruscitti, Maria Gloria Pittelli, Giancarlo Aquino, Roberta Volta, Alice Pappani, Mariarosaria Barrea, Federico Quaini and 4 more

Abstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vanessa PitozziChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.
Paola CarusoChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.
Silvia PontisChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.
Francesca RuscittiChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.
Maria Gloria PittelliChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.ORCID 0000-0003-4851-699X
Giancarlo AquinoChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.
Roberta VoltaChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.
Alice PappaniChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.
Mariarosaria BarreaChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.
Federico QuainiDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.ORCID 0000-0003-2377-4810
Costanza Anna Maria LagrastaDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.ORCID 0000-0003-0552-9205
Antonella Maria NogaraDepartment of Medicine and Surgery, University of Parma, 43126 Parma, Italy.ORCID 0000-0003-2719-7272
Paolo SpagnoloRespiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy.ORCID 0000-0002-1096-0596
Marcello TrevisaniChiesi Farmaceutici S.p.A., Global Research and Preclinical Development, Largo Belloli, 11/A, 43122 Parma, Italy.ORCID 0009-0005-4384-6545

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) remains a progressive and fatal disease despite major advances in antifibrotic therapy. Pirfenidone and nintedanib slow lung function decline, and the PDE4B inhibitor nerandomilast and treprostinil have recently shown promise as next-generation treatments. However, current therapies neither halt nor reverse disease progression, and tolerability issues often limit adherence. We compared the antifibrotic activity and plasma levels of nintedanib administered by either oral gavage or dietary supplementation in a rat model of pulmonary fibrosis. Male Sprague-Dawley rats received intratracheal bleomycin (1 U/kg) on days 0 and 4. From day 7 to day 28, animals were treated with nintedanib (100 mg/kg/day) by either oral gavage or medicated chow. Lung weight, fibrosis biomarkers (procollagen-I, metalloproteinase-7 or MMP7, WNT1-inducible signaling pathway protein or WISP-1), epithelial injury marker KL-6, target engagement biomarkers (Fibroblast Growth Factor 2 or FGF-2, Vascular Endothelial Growth Factor or VEGF), plasma drug levels, and histological fibrosis scores were evaluated. Both administration regimens significantly reduced procollagen-I, WISP-1 and KL-6, and histological fibrosis scores. Oral gavage produced approximately fourfold-higher peak plasma concentrations of nintedanib 30 min after dosing, whereas dietary administration resulted in lower, more stable plasma levels with reduced variability while resulting in comparable antifibrotic efficacy. In conclusion, nintedanib retained robust antifibrotic activity when administered via dietary supplementation despite lower, but continuous, active plasma concentrations. Collectively, these findings indicate that optimizing drug delivery and absorption kinetics may achieve sustained therapeutic efficacy while reducing unnecessary exposure to supratherapeutic concentrations, thereby potentially improving tolerability.

Indexed as

Antifibrotic AgentsBleomycinIndolesPulmonary FibrosisAdministration, OralAnimalsBiomarkersDisease Models, AnimalLungMaleRatsRats, Sprague-DawleyAntifibrotic AgentsBiomarkersBleomycinIndolesnintedanibbiomarkersbleomycinmedicated dietnintedanibtarget engagement

Identifiers

PMID42794585
PMCPMC13607681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.